At the annual meeting of the American Association of Cancer Research (AACR), the focus has converged on the stubborn complexity of the KRAS protein—a long-time "undruggable" target that is finally beginning to yield. Revolution Medicines presented data this week on its experimental drug daraxonrasib, demonstrating a significant, if sober, step forward in the treatment of second-line pancreatic cancer.
The results show that daraxonrasib more than doubled median survival compared to traditional chemotherapy. In the context of pancreatic cancer, a disease notorious for its rapid progression and limited therapeutic options, such a leap is statistically profound. However, the human reality remains modest: the drug extended median survival by six months. It is a margin that highlights both the technical triumph of modern molecular targeting and the immense distance still to be traveled in oncology.
Beyond the clinical data, the meeting served as a forum for institutional stabilization. The director of the National Cancer Institute (NCI) addressed the assembled researchers, seeking to allay persistent anxieties regarding federal funding and the continuity of cancer research initiatives. While last year’s gathering was clouded by uncertainty over the political landscape, this year’s tone was one of cautious pragmatism, balancing the incremental victories of biotechnology with the structural needs of the scientific community.
With reporting from STAT News.
Source · STAT News (Biotech)
